Thermo Fisher Scientific Gross Profit

The latest gross profit for TMO is $19B as of June 2026. That compares with $18B in the prior-year period — up 2.9% year over year. That is below the Healthcare sector average of $65B. Investors often review this figure alongside Thermo Fisher Scientific's historical trend and sector peers before judging valuation or financial health.

Over the past year, TMO's gross profit moved from $18B to $19B — a 2.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Thermo Fisher Scientific's operating scale or balance-sheet position.

Against Healthcare companies, TMO currently prints $19B for gross profit, while the sector average sits near $65B. That is roughly 71.3% below the sector mean. Large gaps often invite a closer look at Thermo Fisher Scientific's growth, margins, and balance sheet.

A gross profit figure of $19B for TMO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting TMO's gross profit ($19B), review year-over-year change from $18B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.